Article Details

Cellect Biotechnology Reports Top Line Data from Phase 1/2 Clinical Trial

Retrieved on: 2021-04-19 12:00:00

Tags for this article:

Click the tags to see associated articles and topics

Cellect Biotechnology Reports Top Line Data from Phase 1/2 Clinical Trial. View article details on hiswai:

Excerpt

Tel Aviv, Israel, April 19, 2021 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: "APOP"), a developer of innovative technology that ...

Article found on: www.globenewswire.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo